Keywords: Novartis, Merck & Co, Fluad, Zostavax, IDSA, Flu vaccine, Shingles, Herpes zoster

Novartis and Merck & Co present strong data on Fluad and Zostavax, respectively, at IDSA meeting

Article | 22 October 2010

Print This

New Phase III data demonstrate that Swiss drug major Novartis’ (NOVN: VX) MF59 adjuvanted influenza vaccine, Fluad, was highly ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in